- SVAX will help Rubedo’s regulatory filings and conduct of Section 2 medical trials for lead program, RLS-1496, within the Kingdom of Saudi Arabia and the Emirate of Dubai
- Partnership builds Rubedo’s footprint as a Hevolution portfolio firm and displays the rising strategic significance of the area in wholesome longevity analysis and the life sciences
SAN FRANCISCO-Rubedo Life Sciences, Inc. (Rubedo), a number one AI-driven, clinical-stage biotech specializing in selective mobile rejuvenation medicines, as we speak introduced a strategic partnership with SVAX throughout the Future Funding Initiative (FII) week in Riyadh. This collaboration will give attention to advancing RLS-1946, Rubedo’s promising lead candidate, by Section 2 medical trials within the Kingdom of Saud Arabia and the Emirate of Dubai.
Expanded Particulars
Strategic Footprint Enlargement: The partnership underscores Rubedo’s integration into Hevolution’s portfolio, highlighting the area’s strategic significance in healthspan analysis and the life sciences.
Key Collaborators: SVAX, a number one Saudi vaccine and biologics producer and medical analysis group (CRO), together with Fakeeh Care Group, will facilitate regulatory filings and medical trial conduct, boosting Rubedo’s medical capabilities within the GCC area. SVAX will help Rubedo’s regulatory filings in Saudi Arabia and the conduct of its deliberate Section 2 Atopic Dermatitis medical trial within the Kingdom and the Emirate of Dubai.
This announcement comes on the heels of the U.S. FDA clearance of the Investigational New Drug (IND) utility for a Section 1b/2a examine with lead drug candidate RLS-1496 in sufferers with actinic keratosis. The Gulf Cooperation Council (GCC) examine is predicted to start in Q2 2026.
“In our earliest conferences with the Hevolution group, we have been satisfied that Saudi Arabia and the GCC had the potential to play a number one position in wholesome longevity science,” stated Rubedo CBO Ali Siam. “This partnership with SVAX will translate this imaginative and prescient into actuality by partnering with one of many main pillars of the Saudi Imaginative and prescient 2030 Nationwide Biotech Technique. We have been honored to be joined within the signing ceremony by our new accomplice, Prof. Mazen Hassanain, Managing Director and CEO of SVAX, and Hevolution Basis SVP of Analysis, HRH Princess Dr. Haya Bint Khaled Bin Bandar Al Saud, a number one voice of healthspan and wholesome longevity each globally and within the Kingdom.”
Prof. Mazen Hassanain, Managing Director and CEO of SVAX stated, “We’re thrilled to be working with the Rubedo group to carry this revolutionary remedy to Saudi Arabia, significantly when circumstances like Atopic Dermatitis and Vitiligo are such excessive areas of unmet want in our area. Ali and I had been discussing our shared imaginative and prescient for catalyzing excessive science within the Kingdom, and because the items of the Saudi Nationwide Biotech Technique got here collectively, this grew to become a transparent win.”
“As a really world longevity therapeutics firm, we’re thrilled to be partnering with SVAX to include affected person populations which have traditionally been underrepresented in medical trials – significantly in Atopic Dermatitis,” stated Rubedo CEO, Dr. Frederick Beddingfield. “This illness has a major remedy burden in Saudi Arabia – research have discovered the prevalence as excessive as 30%1 of the grownup inhabitants – and we all know from printed research and meta-analyses that this illness presents in a different way throughout ethnicities2 and that this has been an ongoing problem in the usual of care worldwide. Incorporating examine websites on the crossroads of three continents will assist present a extra consultant general affected person inhabitants for the analysis of RLS-1496 on this vital situation.”
“At Hevolution, we’re driving world developments in healthspan science. We’re thrilled by Rubedo Life Science’s pivotal step with RLS-1946 getting into Section 2 trials. Teaming up with SVAX for this GCC trial underscores our area’s fast development in medical analysis capabilities and our dedication to elevating healthspan science functionality and capability in Saudi Arabia. This collaboration is about to revolutionize geroscience and fortify the regional biotech panorama,” stated Hevolution SVP of Analysis HRH Princess Dr. Haya Bint Khaled bin Bandar Al Saud.